Inocip-F10 Tablet SR is a sustained-release formulation combining Propranolol 40 mg and Flunarizine 10 mg, designed for the management of migraine prophylaxis and certain cardiovascular conditions. Propranolol, a non-selective beta-adrenergic blocker, exerts its therapeutic effects by reducing heart rate, myocardial contractility, and systemic blood pressure, thereby decreasing cardiac workload and oxygen demand. It is widely utilized in the prevention of migraine attacks, hypertension, angina pectoris, and arrhythmias. Flunarizine, a calcium channel blocker with antihistaminic properties, acts by inhibiting the influx of calcium ions into vascular smooth muscle and neuronal cells, contributing to vasodilation and neuroprotection. This dual-action combination targets both vascular and neurological pathways implicated in migraine pathophysiology, enhancing efficacy in reducing frequency and severity of migraine episodes. The sustained-release formulation ensures prolonged plasma concentration, improving patient compliance and minimizing peak-related adverse effects. Inocip-F10 is indicated for adult patients requiring prophylactic treatment of migraine and may be considered in select cardiovascular disorders where beta-blockade and calcium channel modulation are beneficial. Caution is advised in patients with asthma, bradycardia, heart block, or hypersensitivity to either component. Common adverse effects include fatigue, dizziness, gastrointestinal disturbances, and potential weight gain. Regular monitoring of cardiovascular status is recommended during therapy.